Skip to main content
Premium Trial:

Request an Annual Quote

Tm Bioscience Sells Mayo Foundation on P450-2D6 Test

NEW YORK, Sept. 17 (GenomeWeb News) - Tm Bioscience of Toronto today announced that the Mayo Foundation has signed a two-year agreement to purchase the Tm Tag-It brand P450-2D6 drug metabolism test.

 

The Mayo Foundation of Rochester, Minn., will used the product in the Mayo Medical Laboratories, a facility that provides lab testing services for Mayo as well as other medical centers and hospitals, Tm said in a statement.

 

Tm's P450-2D6 test was launched in June. The company said that Mayo has begun internal validation tests for the product through an early access agreement.

 

The P450-2D6, a test that is designed to identify the presence or absence of mutations common in patients with atypical drug metabolism, is based on Tm's universal array platform and operates on the Luminex xMAP system.

 

The sale of such a microarray-based product is not without controversy. In June, Roche launched its own P450 microarray-based test only to receive a letter from the US Food and Drug Administration questioning the propriety of marketing a microarray-based test as an analyte specific reagent.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.